Clinical Trial Update: Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial (BELA-M-R) is evaluating belatacept for prevention of subclinical antibody-mediated rejection after kidney transplantation in the con…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• belatacept (belatacept)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Kidney Transplant Rejection | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING